Healthcare Industry News: Sideguard
News Release - April 5, 2011
Cappella Medical Announces Senior Management Changes as it Continues to GrowGALWAY, Ireland--(Healthcare Sales & Marketing Network)-- Cappella Medical Devices continues to commercialize its unique Sideguard® coronary sidebranch technology throughout Europe and South America. In order to maximize the ongoing growth, the company announced today an important addition and one key promotion to its senior leadership team.
First, the company is pleased to announce the appointment of Paul Shea as its Chief Executive Officer effective immediately. Paul will be based at Cappella’s headquarters in Galway, Ireland. Paul comes to Cappella with thirty years experience in the medical device industry. Paul recently served as Senior Vice President of Sales at Sentinelle Medical and previously was Vice President of Sales at Traxral, Inc., and Angiodynamics and also held various sales and marketing positions at Boston Scientific Corporation.
In addition, Dr. Art Rosenthal who recently served as Cappella’s CEO has been promoted to Executive Vice Chairman and will be responsible for strategic partnering, clinical development and networking initiatives.
“Paul’s extensive expertise on the commercial side of the medical device field makes him the ideal leader for this active growth stage of the company. Paul is a proven entity in advancing commercial stage businesses and represents the leadership qualities in integrity, commitment and performance which Cappella will build upon to continue its role as pioneer and forerunner in novel bifurcation treatments,” said Eamonn Hobbs, Cappella Medical’s Chairman of the Board.
“We are delighted to have Paul on board working with Art to further drive the change in medical practice towards the use of dedicated stenting for bifurcation disease. The ease of use of our delivery system and the solid clinical experience of almost 1000 implantations makes us confident that Cappella will be the leader in this emerging field by offering true ostial protection and coronary sidebranch preservation,” said Wolfgang Oster, Managing Partner Polytechnos and Cappella board member.
About Cappella Medical Devices
Cappella, Inc. is a medical device company that develops novel solutions for the treatment of complex coronary artery disease (CAD) focused on protecting the coronary sidebranch arteries. Cappella’s Sideguard® coronary sidebranch technology offers interventional cardiologists a straightforward, effective, and easy to use solution that preserves the sidebranch of diseased coronary arteries by protecting the ostium while minimizing plaque shift. The Sideguard delivery system features a proprietary split-sheath, balloon released, technology that ensures precise placement on the ostial borderline. The Sideguard self-expanding, nitinol, stent promotes continuous wall apposition and positive remodeling and its unique trumpet-shaped design conforms to varying characteristics of the sidebranch ostium. Cappella Medical Devices Ltd., Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc. For more information, please visit the Cappella Medical Systems website at www.cappella-med.com.
Source: Cappella Medical Devices
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.